Exclusive: ACR Convergence 2024| Focus Rheums

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Tofacitinib Shows Early Potential for Treating Dermatomyositis

  |  

Currently, the standard therapy for dermatomyositis includes administering corticosteroids, typically with an immunosuppressive agent. But treatment options for refractory dermatomyositis are very limited, Dr. Paik acknowledges.

Although further study of tofacitinib for dermatomyositis is necessary, Dr. Paik says, “Our results seem promising in dermatomyositis. There is no FDA-approved drug for this disease process.”

ADVERTISEMENT
SCROLL TO CONTINUE

She says the decision to proceed with a randomized controlled trial is contingent on the completion and final analysis of all data from this pilot study, which are expected next year.

Carina Stanton is a freelance science journalist based in Denver.

ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Paik JJ, Albayda J, Tiniakou E, et al. Study of tofacitinib in refractory dermatomyositis (STIR): An open label pilot study in refractory dermatomyositis [abstract]. Arthritis Rheumatol. 2018 Oct;70(suppl 10).
  2. Anyanwu CO, Fiorentino DF, Chung L, et al. Validation of the cutaneous dermatomyositis disease area and severity index: Characterizing disease severity and assessing responsiveness to clinical change [abstract]. Arthritis Rheumatol. 2013 Oct:65.

Related Articles

    New Tools for Myositis Diagnosis, Classification & Management

    CHICAGO—At Hot Topics in Myositis, a session at the 2018 ACR/ARHP Annual Meeting, three experts discussed new classification criteria for idiopathic inflammatory myopathies (IIM) and offered practical primers on overlap myositis conditions and inclusion body myositis (IBM). New Myositis Classification Criteria After a 10-year development process, the new EULAR/ACR Classification Criteria for Adult and Juvenile…

    Autoantibodies in Autoimmune Myopathy

    Autoantibodies in Autoimmune Myopathy

    In recent years, scientists and clinicians have learned a great deal about autoantibodies occurring in idiopathic inflammatory myopathies (IIMs). These new discoveries have reshaped our understanding of distinct clinical pheno­types in IIMs. Scientists continue to learn more about how these auto­antibodies shape pathophysiology, diagnosis, disease monitoring, prognosis and optimum treatment. Moving forward, these autoantibodies will…

    Tashatuvango / shutterstock.com

    Myositis-Specific Antibodies Identified

    The idiopathic inflammatory myopathies (IIM) encompass eight categories: 1) dermatomyositis (DM) in adults, 2) juvenile dermatomyositis, 3) amyopathic DM, 4) cancer-associated DM, 5) polymyositis, 6) immune-mediated necrotizing myopathy, 7) inclusion body myositis, and 8) overlap myositis.1 These categories help classify the myopathies based on clinical and histologic features. The incidence of IIM is estimated at…

    State-of-the-Art Approaches to Rheumatic Disease Diagnosis, Management & Treatment

    CHICAGO—Held during the 2018 ACR/ARHP Annual Meeting, the ACR Review Course covered a wide range of topics for rheumatologists—from advances in pain and rheumatic disease management to the intersection of rheumatology and neurology. Session speakers shared insights, as well as state-of-the-art approaches to diagnosis, management and treatment. Inflammatory Myopathies Julie J. Paik, MD, MHS, assistant…